Suppr超能文献

肥大细胞缺陷小鼠空肠黏膜通透性和一氧化氮合酶活性增强。

Enhanced mucosal permeability and nitric oxide synthase activity in jejunum of mast cell deficient mice.

作者信息

Komatsu S, Grisham M B, Russell J M, Granger D N

机构信息

Department of Physiology, LSU Medical Center, Shreveport 71130-3932, USA.

出版信息

Gut. 1997 Nov;41(5):636-41. doi: 10.1136/gut.41.5.636.

Abstract

BACKGROUND

Recent reports have described a modulating influence of nitric oxide (NO) on intestinal mucosal permeability and have implicated a role for mast cells in this NO mediated process.

AIMS

To assess further the contribution of mast cells to the mucosal permeability changes elicited by the NO synthase (NOS) inhibitor NG-nitro-L-arginine methylester (L-NAME), using mast cell deficient (W/Wv) and mast cell replete mice (+/+).

METHODS

Chromium-51 EDTA clearance (from blood to jejunal lumen), jejunal NOS and myeloperoxidase (MPO) activities, and plasma nitrate/nitrite levels were monitored.

RESULTS

The increased EDTA clearance elicited by intraluminal L-NAME in W/Wv mice (4.4-fold) was significantly greater than the response observed in control (+/+) mice (1.8-fold). The exacerbated response in W/Wv mice was greatly attenuated by pretreatment with either dexamethasone (1.3-fold) or the selective inducible NOS inhibitor, aminoguanidine (1.4-fold), and partially attenuated by the mast cell stabiliser, lodoxamide (2.9-fold). Jejunal inducible NOS activity was significantly higher in W/Wv than in +/+ mice, while jejunal MPO was lower in W/Wv mice than in +/+ mice, suggesting that the higher inducible NOS in W/Wv does not result from the recruitment of inflammatory cells into the gut. The higher inducible NOS activity in the jejunum of W/Wv was significantly reduced by dexamethasone treatment.

CONCLUSIONS

Our results suggest that mast cells normally serve to inhibit inducible NOS activity tonically in the gut and that inhibitors of NOS elicit a larger permeability response when this tonic inhibitory influence is released by mast cell depletion.

摘要

背景

最近的报告描述了一氧化氮(NO)对肠黏膜通透性的调节作用,并表明肥大细胞在这一由NO介导的过程中发挥作用。

目的

使用肥大细胞缺陷(W/Wv)小鼠和肥大细胞充足(+/+)小鼠,进一步评估肥大细胞对一氧化氮合酶(NOS)抑制剂N-硝基-L-精氨酸甲酯(L-NAME)引起的黏膜通透性变化的作用。

方法

监测铬-51乙二胺四乙酸(EDTA)清除率(从血液到空肠肠腔)、空肠NOS和髓过氧化物酶(MPO)活性以及血浆硝酸盐/亚硝酸盐水平。

结果

W/Wv小鼠肠腔内L-NAME引起的EDTA清除率增加(4.4倍)显著大于对照(+/+)小鼠(1.8倍)。W/Wv小鼠中这种加剧的反应通过地塞米松预处理(1.3倍)或选择性诱导型NOS抑制剂氨基胍(1.4倍)得到极大减弱,而肥大细胞稳定剂洛度沙胺预处理(2.9倍)使其部分减弱。W/Wv小鼠空肠诱导型NOS活性显著高于+/+小鼠,而W/Wv小鼠空肠MPO低于+/+小鼠,这表明W/Wv小鼠中较高的诱导型NOS并非由炎症细胞向肠道募集所致。地塞米松治疗显著降低了W/Wv小鼠空肠中较高的诱导型NOS活性。

结论

我们的结果表明,肥大细胞通常在肠道中发挥持续抑制诱导型NOS活性的作用,当肥大细胞耗竭释放这种持续的抑制作用时,NOS抑制剂会引发更大的通透性反应。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验